Ruth McBride
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruth McBride has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Jerome L. Fleg
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
3 shared publicationsWilliam E. Boden
VA New England Healthcare System, VA Boston-Jamaica Plain Campus, Boston, MA, USA
3 shared publicationsJeffrey L. Probstfield
Department of Cardiology, University of Washington, School of Medicine, Seattle, WA, USA
2 shared publications- Moti L. Kashyap
VA Long Beach Healthcare System, Long Beach, CA, USA
2 shared publications Patrice Desvigne-Nickens
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
2 shared publicationsTodd Anderson
University of Calgary and Libin Cardiovascular Institute, Foothills Medical Centre, Calgary, AB, Canada
2 shared publications
Latest Publications
- 1 November 2018
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 12 (6) , 1413-1419
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort
- 1 November 2018
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 12 (6) , 1413-1419
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort
- 1 September 2017
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 11 (5) , 1201-1211
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial
- 1 September 2017
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 11 (5) , 1201-1211
Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial
- 1 July 2016
- Published by Elsevier in The American Journal of Medicine
- Vol. 129 (7) , 753.e13-753.e22
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH
- 1 July 2016
- Published by Elsevier in The American Journal of Medicine
- Vol. 129 (7) , 753.e13-753.e22
Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH
- 17 July 2014
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (3) , 288-290
Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial
The results of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial were published in the Journal in 2011.1 This study showed no incremental clinical benefit from the addition of high-dose extended-release niacin (Niaspan, AbbVie) to statin therapy during a 36-month mean follow-up period in 3414 patients who had stable atherosclerotic disease, low baseline levels of high-density lipoprotein (HDL) cholesterol, and elevated triglyceride levels. In that article, we provided data on adverse events resulting in a reduction in the dose or discontinuation of the study drug. These results were largely consistent with the previously established side-effect profile of niacin (e.g., itching, flushing, gastrointestinal symptoms, and increased blood glucose levels). Less common adverse events, including abnormal liver-function tests and myopathy, were also reported.
- 17 July 2014
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (3) , 288-290
Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial
The results of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial were published in the Journal in 2011.1 This study showed no incremental clinical benefit from the addition of high-dose extended-release niacin (Niaspan, AbbVie) to statin therapy during a 36-month mean follow-up period in 3414 patients who had stable atherosclerotic disease, low baseline levels of high-density lipoprotein (HDL) cholesterol, and elevated triglyceride levels. In that article, we provided data on adverse events resulting in a reduction in the dose or discontinuation of the study drug. These results were largely consistent with the previously established side-effect profile of niacin (e.g., itching, flushing, gastrointestinal symptoms, and increased blood glucose levels). Less common adverse events, including abnormal liver-function tests and myopathy, were also reported.
- 1 May 2013
- Published by Elsevier in Journal of Dentistry
- Vol. 41 (5) , 393-403
Measuring the impact of practice-based research networks on member dentists in the Collaboration on Networked Dental and Oral Health Research, CONDOR
- 1 May 2013
- Published by Elsevier in Journal of Dentistry
- Vol. 41 (5) , 393-403
Measuring the impact of practice-based research networks on member dentists in the Collaboration on Networked Dental and Oral Health Research, CONDOR
- Top Cited Papers
- 15 December 2011
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 365 (24) , 2255-2267
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk.
- 15 December 2011
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 365 (24) , 2255-2267
Top Cited PapersNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk.